electroCore, Inc. (NASDAQ:ECOR) Short Interest Up 34.5% in January

electroCore, Inc. (NASDAQ:ECOR) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 118,600 shares, a growth of 34.5% from the January 15th total of 88,200 shares. Based on an average daily trading volume, of 121,900 shares, the short-interest ratio is currently 1.0 days. Currently, 2.3% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Separately, HC Wainwright upped their target price on shares of electroCore from $22.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th.

Institutional Investors Weigh In On electroCore

A number of institutional investors and hedge funds have recently modified their holdings of ECOR. JPMorgan Chase & Co. raised its holdings in shares of electroCore by 31,250.0% in the 4th quarter. JPMorgan Chase & Co. now owns 3,762 shares of the company’s stock valued at $61,000 after purchasing an additional 3,750 shares during the period. DnB Asset Management AS bought a new stake in shares of electroCore in the 4th quarter valued at about $180,000. HighTower Advisors LLC bought a new stake in shares of electroCore in the 3rd quarter valued at about $255,000. NewEdge Advisors LLC bought a new stake in shares of electroCore in the 4th quarter valued at about $274,000. Finally, Jane Street Group LLC acquired a new position in electroCore in the 4th quarter valued at about $278,000. 26.74% of the stock is owned by institutional investors.

electroCore Price Performance

NASDAQ ECOR traded up $0.24 on Friday, reaching $17.41. The company had a trading volume of 53,710 shares, compared to its average volume of 88,829. electroCore has a 1-year low of $5.32 and a 1-year high of $18.67. The company’s fifty day moving average is $15.98 and its 200-day moving average is $11.04.

electroCore Company Profile

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.